Spaced PKC Activator Dosing Regimen for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for upregulating Protein Kinase C (PKC) face challenges in maintaining beneficial effects due to subsequent downregulation, which limits the duration of cognitive and therapeutic benefits in treating neurodegenerative diseases like Alzheimer's.
Innovation Solution
A spaced or intermittent dosing regimen of PKC activators, where the PKC activator is administered once a week for three consecutive weeks followed by cessation for three consecutive weeks, to minimize downregulation and sustain cognitive benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If continuous administration of PKC activator is used, then cognitive benefits are initially achieved, but subsequent downregulation occurs limiting duration of action
Solution Approach 1:
The patent implements periodic action by establishing a dosing regimen of three consecutive weeks of administration followed by three consecutive weeks of cessation. This intermittent pattern allows PKC activation during treatment periods while preventing chronic downregulation through scheduled pauses, thereby extending the duration of cognitive benefits and maintaining reliability of PKC levels.
2Reliability
If frequent dosing is used, then therapeutic effect is maintained, but downregulation accelerates reducing long-term efficacy
Solution Approach 1:
The patent applies periodic action through a structured on/off cycle where PKC activator is administered for three weeks followed by a three-week break. This timing pattern maintains PKC level stability during treatment while preventing accelerated downregulation through strategic pauses, thereby extending the duration of therapeutic benefits.
Solution Approach 2:
The patent ensures continuity of useful action by repeating the three-week treatment cycle multiple times over extended periods. This repeated cycling maintains continuous therapeutic benefit accumulation while each cycle prevents downregulation through its built-in cessation phase, achieving both reliability and extended duration.
3Speed
If high dose administration is used, then rapid PKC upregulation is achieved, but subsequent downregulation is more severe
Solution Approach 1:
The patent resolves this contradiction by using periodic action with a three-week on/off cycle. During the three-week treatment phase, PKC upregulation occurs at an effective rate. The subsequent three-week cessation prevents severe downregulation by allowing PKC levels to stabilize, thereby maintaining reliability while achieving rapid initial upregulation.
Data Source
AI summary
Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.